Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

BACKGROUND: Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. DESIGN AND METHODS: Oral cyclophosphamide, thalidomide, and dexamethasone was...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Morgan, Gareth J., Davies, Faith E., Gregory, Walter M., Bell, Sue E., Szubert, Alexander J., Navarro Coy, Nuria, Cook, Gordon, Feyler, Sylvia, Johnson, Peter R.E., Rudin, Claudius, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Russell, Nigel H., Jackson, Graham H., Child, J. Anthony
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2012
Assuntos:
Original Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291601/
https://ncbi.nlm.nih.gov/pubmed/22058209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.043372
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados